Elucent Medical LLC

3520 Horseshoe Bend Court

Brookfield, WI 53045

Email: info@elucentmedical.com

Web Site: www.elucentmedical.com

Management: Laura G. King, Co-founder & CEO; Dan van der Weide, PhD, Fred T. Lee, MD, Chris Brace, PhD, Lee Wilke, MD and Elizabeth Burnside, MD, Co-founders (all University of Wisconsin)

Company Launched: January 2014

Financing To Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: University of Wisconsin

Industry Segment: Oncology Devices

Business: Elucent Medical aims to commercialize a noninvasive alternative to hook-wire procedures for breast cancer. Its wireless marker tag and detection system helps locate breast abnormalities and predict margins during surgical excision. Founding CEO Laura King is a former GE Healthcare executive and also previously led surgical ablation start-up NeuWave Medical.

LuminaCare Solutions Inc.

100 TradeCenter

Suite G-700

Office 804

Woburn, MA 01801

Email: info@luminacaresolutions.com

Web Site: www.luminacaresolutions.com

Management: David Howe, PhD, Co-founder & CEO; Stephen R. Chiricosta, Co-founder and COO

Company Launched: October 2013

Financing To Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: NA

Industry Segment: Big Data

Business: LuminaCare is developing cloud-based predictive analytics for hospitals to rapidly identify (in less than 24 hours) the correct treatment for patients’ bacterial infections. Personalizing treatment should help hospitals avoid readmissions and over time reduce antibiotic resistance. CEO David Howe previously held executive positions at Vertex Pharmaceuticals and AstraZeneca.

PDC*line Pharma

c/o GATE1 incubator

Petite Halle

31 rue Gustave Eiffel

38000 Grenoble, France

Email: l.levy@pdc-line-pharma.com

Web Site: www.pdcline-pharma.com

Management: Laurent Levy, CEO; Joel Plumas, PhD, CSO

Company Launched: March 2014

Financing To Date: Undisclosed

Investors: Undisclosed

Partners/Alliances: Etablissement Français du Sang (EFS)

Industry Segment: Cancer Therapeutics

Business: PDC*vac is a therapeutic cancer vaccine platform based on PDC*line, a proprietary plasmacytoid dendritic cell line developed by the EFS, the French national blood service. The start-up says PDC*vac platform can be used to target virtually any cancer: PDC*mel is in Phase I melanoma trials, and PDC*Lung is in early development for lung cancer.

Neuway Pharma GMBH

Theresienstrasse 680333 Munich, Germany

Phone: +49 89 21994116

Email: strohmenger@wellington-partners.com

Web Site: NA

Management: Heiko Manninga, PhD, CSO; Rainer Strohmenger, PhD, Chairman (Wellington Partners)

Company Launched: April 2014

Financing To Date: €2.70 million Series A

Investors: Wellington Partners

Partners/Alliances: NA

Industry Segment: Drug Development

Business: Neuway is the first spin-out from the Life Science Inkubator-Caesar. It will undertake preclinical and clinical development of innovative therapeutics for orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

Emergings In Brief, June 2014

More from Archive

More from Scrip